EUVIMEDEUVIMED entdecken
Crossref

Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients

Andréa Tavares Dantas, Anderson Rodrigues de Almeida, Marina Ferraz Cordeiro, Priscilla Stela Santana de Oliveira, José Arion da Silva Moura, Michelly Cristiny Pereira, Moacyr Jesus Barreto de Melo Rêgo, Rafaela Silva Guimarães Gonçalves, Marina Galdino da Rocha Pitta, Angela Luzia Branco Pinto Duarte, Maira Galdino da Rocha Pitta

Pharmacological Reports · 2026

DOI: 10.1007/s43440-025-00809-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2026. Verfasst von Andréa Tavares Dantas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital das Clínicas da Universidade Federal de Pernambuco, Recife, PE, Brazil. Hauptthemen laut MEDLINE: Leukocytes, Mononuclear, Scleroderma, Systemic, Thiazolidines, Cytokines. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. MATERIALS AND METHODS: PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). RESULTS: LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. CONCLUSIONS: Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocytes, MononuclearScleroderma, SystemicThiazolidinesCytokinesHumansFemaleMaleMiddle AgedInterleukin-17AdultPPAR gammaChemokine CCL2Interleukin-4Interleukin-10AgedMolecular Docking SimulationInterleukin-8

Stichwörter der Autor:innen

AutoimmunityFibrosisInflammationTreatment

Substanzen

Interleukin-17ThiazolidinesCytokinesPPAR gammaChemokine CCL2Interleukin-4Interleukin-10Interleukin-8CCL2 protein, humanIL17A protein, human

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital das Clínicas da Universidade Federal de Pernambuco, Recife, PE, Brazil.
  • Laboratório de Imunomodulação e Novas Abordagens Terapêuticas (LINAT), Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino (NUPIT SG), Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, 1235 - Cidade Univer…
  • Laboratório de Planejamento e Síntese de Fármacos, Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Tavares Dantas, A., Rodrigues de Almeida, A., Ferraz Cordeiro, M., Santana de Oliveira, P. S., da Silva Moura, J. A., Pereira, M. C., Barreto de Melo Rêgo, M. J., Silva Guimarães Gonçalves, R., Galdino da Rocha Pitta, M., Branco Pinto Duarte, A. L., & Galdino da Rocha Pitta, M. (2026). Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients. Pharmacological Reports. https://doi.org/10.1007/s43440-025-00809-3

Vancouver

Tavares Dantas A, Rodrigues de Almeida A, Ferraz Cordeiro M, Santana de Oliveira PS, da Silva Moura JA, Pereira MC, et al. Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients. Pharmacological Reports. 2026. doi:10.1007/s43440-025-00809-3

BibTeX
@article{TavaresDantas2026,
  author = {Tavares Dantas, Andréa and Rodrigues de Almeida, Anderson and Ferraz Cordeiro, Marina and Santana de Oliveira, Priscilla Stela and da Silva Moura, José Arion and Pereira, Michelly Cristiny and Barreto de Melo Rêgo, Moacyr Jesus and Silva Guimarães Gonçalves, Rafaela and Galdino da Rocha Pitta, Marina and Branco Pinto Duarte, Angela Luzia and Galdino da Rocha Pitta, Maira},
  title = {Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients},
  journal = {Pharmacological Reports},
  year = {2026},
  doi = {10.1007/s43440-025-00809-3}
}
Kostenlos starten →